Immunotherapy for Non-melanoma Skin Cancer

Shalhout, Sophia Z; Emerick, Kevin S.; Kaufman, Howard L.; Miller, David M.

doi:10.1007/s11912-021-01120-z

Cited by 70 publications

(55 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As an example, BodyMapR is currently being used by the Project Data Sphere-supported MCC patient registry. 3 Therefore, modifications have been made to incorporate specific CTC salient to MCC. For example, the MCC BodyMapR application has incorporated sidebar selectors with disease-specific information such as Merkel Cell polyoma virus-related data ( Supplementary Figure S4 ).…”

Section: Resultsmentioning

confidence: 99%

BodyMapR: an R package and Shiny application designed to generate anatomical visualizations of cancer lesions

Miller

Shalhout

2022

JAMIA Open

Self Cite

View full text Add to dashboard Cite

Objectives Structured real-world data (RWD), such as those found in cancer registries, provide a rich source of information regarding the natural history of cancer. Interactive data visualizations of cancer lesions can provide insights into certain clinical tumor characteristics (CTC). Software that can be integrated into an oncological data collection effort and generate anatomical data visualizations of CTC are limited. Materials and Methods We created BodyMapR: an R package and Shiny application that generates anatomical visualizations of cancer lesions from structured data. Results BodyMapR is a Shiny application that transposes structured data from REDCap® onto an anatomical map to yield an interactive data visualization. Conclusions BodyMapR is freely available under the MIT license and can be obtained from GitHub. BodyMapR is executed in R and deployed as a Shiny application. It can be integrated into an existing cancer research platform and produces an interactive data visualization of CTC.

show abstract

Section: Resultsmentioning

confidence: 99%

BodyMapR: an R package and Shiny application designed to generate anatomical visualizations of cancer lesions

Miller

Shalhout

2022

JAMIA Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other treatments options such as the PD-L1 inhibitors pebrolizumab and cepilumab have been used for the treatment of advanced-metastatic BCCs and SCCs but still there are no literature data for their use in advanced BSC [ 56 ].…”

Section: Resultsmentioning

confidence: 99%

Basosquamous Carcinoma: A Commentary

Fotiadou

Apalla

Lazaridou

2021

Cancers

View full text Add to dashboard Cite

Basosquamous carcinoma is a rare, aggressive non-melanoma skin cancer with features that lie between those of basal cell carcinoma and squamous cell carcinoma. A lot of controversy has been raised around the classification, pathogenesis, histologic morphology, biologic behavior, prognosis and management of this tumor. This is a narrative review based on an electronic search of articles published in PubMed in English language which had in their title the terms “basosquamous carcinoma” and/or “metatypical carcinoma of the skin”. The aim of this review was to summarize and evaluate current data regarding epidemiology, clinical presentation, dermoscopic and histopathologic characteristics, as well as the genetics and management of BSC, in order to shed some more light onto this intriguing entity. As a conclusion, dermoscopy, deep incisional biopsies and immunohistologic techniques (Ber-EP4) should be applied in clinically suspicious lesions in order to achieve an early diagnosis and better prognosis of this tumor. Surgical treatments, including wide excision and Mohs’ micrographic surgery, remain the treatment of choice. Finally, vismodegib, a Hedgehog pathway inhibitor, must be thoroughly investigated, with large controlled trials, since it may offer an alternative solution to irresectable or difficult-to-treat, locally advanced cases of basosquamous carcinoma.

show abstract

“…The immune system has a pivotal role in developing cSCC, as shown by the frequent growth of cSCC in the skin of immunocompromised patients ( Omland et al, 2018 ). In recent years, checkpoint inhibitors, particularly the PD-1 inhibitors Cemiplimab and Pembrolizumab, have been approved to treat unresectable or metastatic cutaneous squamous cell carcinoma ( Shalhout et al, 2021 ). Human cSCC have enhanced expression of PD-1 and CTLA-4 ( Gambichler et al, 2017 ), and blocking these proteins results in improved infiltration of T cells (CD4 + and CD8 + ), hindering the development of SCC in animal models ( Belai et al, 2014 ).…”

Section: Ecm and Remodeling In Therapeutic Resistancementioning

confidence: 99%

The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance

Fromme

Zigrino

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

The extracellular matrix remodeling in the skin results from a delicate balance of synthesis and degradation of matrix components, ensuring tissue homeostasis. These processes are altered during tumor invasion and growth, generating a microenvironment that supports growth, invasion, and metastasis. Apart from the cellular component, the tumor microenvironment is rich in extracellular matrix components and bound factors that provide structure and signals to the tumor and stromal cells. The continuous remodeling in the tissue compartment sustains the developing tumor during the various phases providing matrices and proteolytic enzymes. These are produced by cancer cells and stromal fibroblasts. In addition to fostering tumor growth, the expression of specific extracellular matrix proteins and proteinases supports tumor invasion after the initial therapeutic response. Lately, the expression and structural modification of matrices were also associated with therapeutic resistance. This review will focus on the significant alterations in the extracellular matrix components and the function of metalloproteinases that influence skin cancer progression and support the acquisition of therapeutic resistance.

show abstract

Immunotherapy for Non-melanoma Skin Cancer

Cited by 70 publications

References 65 publications

BodyMapR: an R package and Shiny application designed to generate anatomical visualizations of cancer lesions

BodyMapR: an R package and Shiny application designed to generate anatomical visualizations of cancer lesions

Basosquamous Carcinoma: A Commentary

The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance

Contact Info

Product

Resources

About